The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial evaluating the activity, safety and ...

AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC). ENGOT-OV43/KEYLYNK-001: A phase III, ...

TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell ...

Results from innovaTV 301 intended to serve as pivotal confirmatory trial for U.S. accelerated approval and to support global regulatory applications “Patients with cervical cancer have few treatment ...

Data from the study selected as a late-breaking abstract at ESMO, oral presentation is at 17:04 CEST on Sep 21, 2020 Genmab A/S (Nasdaq: GMAB) announced today that results from the phase 2 innovaTV ...

Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysis Trial results to be submitted for presentation at a ...

COPENHAGEN, Denmark, and BOTHELL, Wash.; September 19, 2021 - Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today presented interim data from two cohorts of the Phase 1b/2 innovaTV 205 ...

InnovaTV 204 study evaluated tisotumab vedotin in recurrent or metastatic cervical cancer Data from the study selected as a late-breaking abstract at ESMO, oral presentation is at 17:04 CEST on Sep 21 ...

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today presented interim data from two cohorts of the phase 1b/2 innovaTV 205 ...